July 17, 2024

Non-invasive Uterine Fibroid Treatment Segment is the Largest Segment Driving the Growth of U.S. Uterine Fibroid Treatment Market

The U.S. Uterine Fibroid Treatment Market is estimated to be valued at US$ 269.4 Mn or Million in 2023 and is expected to exhibit a CAGR of 4.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview
Uterine fibroids are benign tumors that grow in or on the walls of the uterus. Non-invasive treatment options such as MRgFUS and UAE help reduce or eliminate symptoms associated with uterine fibroids such as heavy menstrual bleeding and pelvic pressure or pain without surgical incision.

Market key trends
One of the key trends in the U.S. uterine fibroid treatment market is the increasing adoption of minimally invasive treatment procedures. Procedures such as MRI-guided focused ultrasound (MRgFUS) and uterine artery embolization (UAE) allow treating fibroids without surgical incision resulting in shorter hospital stay and recovery time. For instance, according to a study published in 2023, MRgFUS treatment demonstrated a 76.7% reduction in bulk fibroid volume and significant improvement in quality of life and symptoms among patients at 6 months post-treatment.
Market key trends:
The U.S. uterine fibroid treatment market has witnessed significant growth in recent years due to rising adoption of minimally invasive procedures. Some of the major trends in the market include growing preference for non-invasive procedures such as magnetic resonance guided focused ultrasound surgery (MRgFUS) and increased adoption of ultrasound guided focused ultrasound procedures. MRgFUS allows localized ablation of uterine fibroids without incisions. It provides advantages like reduced pain, bleeding and quick recovery time.

SWOT Analysis
Strengths: Advanced non-invasive treatment options such as focused ultrasound surgery and radiofrequency ablation cause less pain and quicker recovery. Rising awareness about uterine fibroid symptoms and treatment alternatives.
Weaknesses: High cost associated with newer treatment procedures such as MRI-guided focused ultrasound surgery limits widespread adoption. Lack of insurance coverage for some procedures.
Opportunities: Increasing investment by market players to develop innovative products. Growing geriatric female population susceptible to fibroids.
Threats: Presence of alternative treatment methods such as myomectomy and hysterectomy. Risks related to invasive surgical procedures.

Key Takeaways
The U.S. uterine fibroid treatment market size was valued at US$ 269.4 million in 2023 and is expected to reach over US$ 370 million by 2030, expanding at a CAGR of 4.0% during the forecast period. Factors such as rising awareness about uterine fibroid symptoms and increasing adoption of minimally invasive treatment options are expected to drive the market.

By region, the Northeast region currently dominates the U.S. market due to high prevalence of uterine fibroids and availability of advanced healthcare facilities. States like New York and Pennsylvania have emerged as major markets. However, regions in the South are projected to witness fastest growth over the coming years.

Key players operating in the U.S. uterine fibroid treatment market include Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., Karl Storz SE & Co. KG, Myovant Sciences GmbH, Halt Medical, Inc., LiNA Medical ApS, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH. Majority of these companies focus on development of innovative minimally invasive technologies for uterine fibroid treatment.